Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METZOLIMOS: Sirolimus Combination in Advanced Solid Tumors and Osteosarcoma
NCT02517918Phase 1Completed
- Sponsor
- Institut Bergonié
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in solid tumor and osteosarcoma (OS), sponsored by Institut Bergonié. Primary endpoints: Dose-Limiting Toxicities at 28 days and 6-month Non-progression Rate. Started Feb 2015; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
solid tumorosteosarcoma (OS)
Beyond the preview
Go deeper on NCT02517918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02517918.